These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750 [TBL] [Abstract][Full Text] [Related]
3. High intensity focused ultrasound with Focal-One Perez-Reggeti JI; Sanchez-Salas R; Sivaraman A; Linares Espinos E; de Gracia-Nieto AE; Barret E; Galiano M; Rozet F; Fregeville A; Renard-Penna R; Cathala N; Mombet A; Prapotnich D; Cathelineau X Actas Urol Esp; 2016 Dec; 40(10):608-614. PubMed ID: 27543259 [TBL] [Abstract][Full Text] [Related]
4. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Crouzet S; Chapelon JY; Rouvière O; Mege-Lechevallier F; Colombel M; Tonoli-Catez H; Martin X; Gelet A Eur Urol; 2014 May; 65(5):907-14. PubMed ID: 23669165 [TBL] [Abstract][Full Text] [Related]
5. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. Kanthabalan A; Peters M; Van Vulpen M; McCartan N; Hindley RG; Emara A; Moore CM; Arya M; Emberton M; Ahmed HU BJU Int; 2017 Aug; 120(2):246-256. PubMed ID: 28258616 [TBL] [Abstract][Full Text] [Related]
6. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. Duwe G; Boehm K; Haack M; Sparwasser P; Brandt MP; Mager R; Tsaur I; Haferkamp A; Höfner T World J Urol; 2023 May; 41(5):1293-1299. PubMed ID: 36920492 [TBL] [Abstract][Full Text] [Related]
7. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study. Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211 [TBL] [Abstract][Full Text] [Related]
9. Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis. Albisinni S; Aoun F; Bellucci S; Biaou I; Limani K; Hawaux E; Peltier A; van Velthoven R J Endourol; 2017 Jan; 31(1):14-19. PubMed ID: 27799004 [TBL] [Abstract][Full Text] [Related]
10. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes. Feijoo ER; Sivaraman A; Barret E; Sanchez-Salas R; Galiano M; Rozet F; Prapotnich D; Cathala N; Mombet A; Cathelineau X Eur Urol; 2016 Feb; 69(2):214-20. PubMed ID: 26164416 [TBL] [Abstract][Full Text] [Related]
11. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918 [TBL] [Abstract][Full Text] [Related]
12. Focal Treatment for Unilateral Prostate Cancer Using High-Intensity Focal Ultrasound: A Comprehensive Study of Pooled Data. Albisinni S; Mélot C; Aoun F; Limani K; Peltier A; Rischmann P; van Velthoven R J Endourol; 2018 Sep; 32(9):797-804. PubMed ID: 29790383 [TBL] [Abstract][Full Text] [Related]
13. High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response. Dason S; Wong NC; Allard CB; Hoogenes J; Orovan W; Shayegan B Int Braz J Urol; 2018; 44(2):248-257. PubMed ID: 29211405 [TBL] [Abstract][Full Text] [Related]
14. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Murat FJ; Poissonnier L; Rabilloud M; Belot A; Bouvier R; Rouviere O; Chapelon JY; Gelet A Eur Urol; 2009 Mar; 55(3):640-7. PubMed ID: 18508188 [TBL] [Abstract][Full Text] [Related]
15. Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial. Kaufmann B; Raess E; Schmid FA; Bieri U; Scherer TP; Elleisy M; Donati OF; Rupp NJ; Moch H; Gorin MA; Mortezavi A; Eberli D BJU Int; 2024 Apr; 133(4):413-424. PubMed ID: 37897088 [TBL] [Abstract][Full Text] [Related]
16. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial. Westhoff N; Ernst R; Kowalewski KF; Derigs F; Neuberger M; Nörenberg D; Popovic ZV; Ritter M; Stephan Michel M; von Hardenberg J Eur Urol Focus; 2023 Mar; 9(2):283-290. PubMed ID: 36344395 [TBL] [Abstract][Full Text] [Related]
17. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. Pfeiffer D; Berger J; Gross AJ BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703 [TBL] [Abstract][Full Text] [Related]
18. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. Reddy D; Peters M; Shah TT; van Son M; Tanaka MB; Huber PM; Lomas D; Rakauskas A; Miah S; Eldred-Evans D; Guillaumier S; Hosking-Jervis F; Engle R; Dudderidge T; Hindley RG; Emara A; Nigam R; McCartan N; Valerio M; Afzal N; Lewi H; Orczyk C; Ogden C; Shergill I; Persad R; Virdi J; Moore CM; Arya M; Winkler M; Emberton M; Ahmed HU Eur Urol; 2022 Apr; 81(4):407-413. PubMed ID: 35123819 [TBL] [Abstract][Full Text] [Related]